Optimal Duration of Urinary Catheterization After Right-Sided Colectomy

November 5, 2026 updated by: Sacha Broccard, University of Southern California

Optimal Duration of Urinary Catheterization After Right-Sided Colectomy: Prospective, Randomized, Non-inferiority Trial

The goal of this prospective, randomized trial is to determine the optimal duration of urinary catheterization in patients that receive elective, right-sided colectomy. The main objectives of this study are:

  • To compare rates of urinary retention in patients with post operative urinary catheter duration of 0 days and 1 day following right-sided colectomy.
  • To compare rates of urinary tract infection (UTI) in patients with postoperative urinary catheter duration of 0 days and 1 day following right-sided colectomy.

Enrolled participants will be randomized to one of two groups, immediate removal of urinary catheter at the conclusion of the operation or removal of urinary catheter on post operative day one.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Urinary catheterization is indicated for various operations conducted by colorectal surgeons. This process allows a tube to be inserted into the bladder to provide decompression while the patient is anesthetized. Prolonged urinary catheter placement is associated with urinary retention, urinary tract infections, and increased hospital length of stay. Clinical guidelines recommend urinary catheter discontinuation within 24 hours of operation but there is mixed evidence to support this recommendation. Further, there is a paucity of data that investigates optimal urinary catheter duration in specific colorectal surgery operations.

This prospective, randomized clinical trial aims to identify the optimal urinary catheter duration for patients undergoing elective, right-sided colectomy. Patients will be randomized into two groups: 1) urinary catheter discontinuation at the completion of surgery, or 2) urinary catheter discontinuation on post operative day 1. The primary objective is to compare rates of urinary retention between groups. The investigators hypothesize that patients with immediate urinary catheter discontinuation will have reduced rates of urinary retention and urinary tract infections compared to the group with urinary catheters maintained until post operative day 1.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
190

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • California
      • Los Angeles, California, United States, 90033
      • Los Angeles, California, United States, 90033

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 18 years or older.
  • Scheduled for elective ileocecectomy, right hemicolectomy, or extended right hemicolectomy using an open, laparoscopic, or robotic approach.
  • American Society of Anesthesiologists physical status class I-III.
  • Ability and willingness to provide written informed consent.

Exclusion Criteria:

  • History of urinary tract malignancy.
  • Emergent or urgent surgery.
  • Right hemicolectomy performed with another major surgical procedure on the same day.
  • Genitourinary tract injury during surgery that precludes participation.
  • History of urinary retention following a previous procedure, surgery, or urinary catheter removal.
  • History of urinary retention that is not being actively treated.
  • Neurogenic bladder.
  • Chronic indwelling Foley catheter or suprapubic catheter.
  • History of cystectomy or a surgically created urinary conduit, including a neobladder or ileal conduit.
  • Chronic kidney disease greater than stage 2.
  • History of chronic urinary tract infection.
  • Current extravesicular or enterourethral fistula.
  • Perioperative epidural catheter placement.
  • Incarceration.
  • Inability or unwillingness to provide informed consent.
  • Pregnancy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Immediate Catheter Removal

Participants will undergo urinary catheter removal immediately after completion of surgery, in the operating room on post operative day 0.
Procedure: Immediate Urinary Catheter Removal

Removal of the urinary catheter immediately after elective right hemicolectomy before leaving the operating room.

Other Names:
  • POD0 catheter removal
  • Immediate Foley Removal
Active Comparator: Postoperative Day 1 Catheter Removal

Participants will undergo urinary catheter removal on post operative day 1.
Procedure: Postoperative Day 1 Urinary Catheter Removal

Removal of the intra-operatively placed Foley urinary catheter on the day after elective right-sided colectomy, post-operative day one.

Other Names:
  • removal POD1 catheter removal
  • next-day Foley removal

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Percentage of Participants With Post Operative Urinary Retention
Time Frame: From initial post operative urinary catheter removal through hospital discharge, assessed up to 90 days.

Post operative urinary retention will be identified by inability to void within 8 hours after catheter removal, associated suprapubic fullness and/or tenderness, and a bladder scan volume greater than 300 mL; or by spontaneous voiding with urinary symptoms and a post-void residual volume greater than 300 mL. Symptoms include suprapubic pain or fullness, bladder pressure, incomplete emptying, or straining.
From initial post operative urinary catheter removal through hospital discharge, assessed up to 90 days.

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Percentage of Participants With Urinary Tract Infection
Time Frame: From post operative day one through hospital discharge, assessed up to 90 days.

Urinary tract infection will be identified by clinical signs or symptoms such as suprapubic pain or tenderness, dysuria, hematuria, or urinary frequency, together with a urine culture showing more than 100,000 colony-forming units/mL of bacteria. Urinalysis and urine culture will be obtained only when infection is clinically suspected.
From post operative day one through hospital discharge, assessed up to 90 days.
Postoperative Hospital Length of Stay
Time Frame: From post operative day one through hospital discharge, assessed up to 90 days.

Number of inpatient hospital days from the day of surgery to the day of discharge.
From post operative day one through hospital discharge, assessed up to 90 days.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Southern California

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 30, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 30, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 30, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 2, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 5, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 12, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 12, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 5, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • HS-25-00655

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Consent does not permit sharing; will revisit

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings